Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Regeneron Pharmaceuticals, Inc. (REGN) had Return on Investments of 2.52% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$3.03B |
|
$808.70M |
|
$464.30M |
|
$2.56B |
|
$2.44B |
|
$591.70M |
|
$313.30M |
|
$905.00M |
|
$905.00M |
|
$808.70M |
|
$808.70M |
|
$808.70M |
|
$808.70M |
|
$591.70M |
|
$718.60M |
|
106.70M |
|
111.20M |
|
$7.58 |
|
$7.27 |
|
| Balance Sheet Financials | |
$17.57B |
|
$4.69B |
|
$19.97B |
|
$37.55B |
|
$3.57B |
|
$2.70B |
|
$4.59B |
|
$8.16B |
|
$29.39B |
|
$28.22B |
|
$29.39B |
|
108.20M |
|
| Cash Flow Statement Financials | |
$1.05B |
|
$647.50M |
|
$-1.09B |
|
$2.49B |
|
$3.09B |
|
$604.00M |
|
$255.70M |
|
$-93.80M |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.93 |
|
-- |
|
-- |
|
0.08 |
|
0.09 |
|
84.67% |
|
19.54% |
|
19.54% |
|
-- |
|
29.88% |
|
26.70% |
|
$815.80M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.15 |
|
0.54 |
|
165.25 |
|
2.75% |
|
2.87% |
|
2.15% |
|
|
Return on Investments |
2.52% |
$271.60 |
|
$7.34 |
|
$9.40 |
|